By Radu-Sorin Marinas, Jan Lopatka and Tsvetelia Tsolova
BUCHAREST/PRAGUE/SOFIA (Reuters) - Pfizer has slashed in half the volume of COVID-19 vaccines it will deliver to some EU countries this week, government officials said on Thursday, as frustration over the U.S. drugmaker's unexpected cut in supplies grows.
Romania will get 50% of its planned volume this week and supplies will only improve gradually, with deliveries not returning to normal until the end of March, Deputy Health Minister Andrei Baciu told Reuters.
It was a similar situation in Poland which on Monday received 176,000 doses, a drop of around 50% from what was expected, authorities said.
The Czech government was bracing for the disruption to last weeks, slowing its vaccination campaign just as the second dose of vaccinations get under way.
"We have to expect that there will be a reduction in the number of open vaccination appointments in the following three weeks," Health Minister Jan Blatny told reporters on Thursday, with Pfizer deliveries falling by about 15% this week and as much as 30% for the following two weeks.
Pfizer and its German partner BioNTech have declined to comment on the cuts beyond their statement last week, which announced cuts to deliveries as they ramp up manufacturing in Europe.
Some countries reckon they can handle it. Norway has an emergency stockpile and will continue administering doses as planned, the government's public health body said.
The U.S. drugmaker has told Bulgaria and Poland it will replace missing doses, top officials said.
But Denmark's Serum Institute said its 50% loss of shots this week would lead to a 10% shortfall for the first quarter.
With governments across the region still reeling from the surprise cuts, officials say the reductions are undermining their efforts to inoculate their citizens and tame the pandemic which has killed more than 2 million people.
On Wednesday, Italy threatened legal action against Pfizer.
In Hungary, where the authorities gave the go ahead for the use of Britain's AstraZeneca and Russia's Sputnik V vaccines ahead of the EU drug regulator, a senior official called on Brussels to try and ensure deliveries from Pfizer and other vaccine makers would stick to schedule.
"We would be happy if the (European) Commission could take steps as soon as possible to ensure that Pfizer and other manufacturers would change deliveries," Prime Minister Viktor Orban's chief of staff Gergely Gulyas said.
The problem has spread to countries outside the trading bloc too - Canada is facing delays as is Switzerland, where the mountain canton of Grisons got only 1,000 shots from Pfizer this week, far short of the 3,000 it had been anticipating.
(Reporting by Radu-Sorin Marinas in Bucharest, Jan Lopatka in Prague, Tsvetelia Tsolova in Sofia, Francesco Guarascio in Brussels, Alan Charlish in Warsaw, Jacob Gronholt-Pedersen in Copenhagen, Krisztina Than in Budapest, Gwladys Fouche in Oslo, John Miller in Zurich and Ludwig Burger in Frankfurt; Writing by Josephine Mason, Editing by William Maclean)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)